Type 2 Diabetes

Diana Isaacs, PharmD, discusses the Build Back Better Act, the potential impact of a monthly spending cap on insulin, and reflects on the progress that has been made in regard to insulin affordability during the 100-year anniversary of the discovery of insulin.

From 1976 to 2018, data show the prevalence of obesity in the United States increased from 6.2% to 32.7%.

Adults aged 18–29 years (87%) with diabetes were more likely to report missed medical care during COVID-19, compared to those aged 30–59 years (63%) or ≥60 years (26%).

A recent analysis found patients with diabetes were about 26% less likely to notice symptoms of atrial fibrillation and more likely to experience more comorbidities than their counterparts without diabetes.

An analysis of survey data from patients in multiple countries provides clinicians with an overview of the effects of self-isolation during the COVID-19 pandemic on diabetes management, including access to insulin and blood glucose fluctuations.

Data from the SWISS-AF study is providing clinicians with insight into the likelihood of patients to perceive symptoms of atrial fibrillation based on whether or not they had diabetes.

Investigators noted that several types of AID systems improved Time-in-Range and HbA1c with minimal concerns around severe hypoglycemia in type 1 diabetes care.

A retrospective study leveraging 2-3 years of data found long-term HbA1c control was a greater predictor of COVID-19 severity than a single, contemporary HbA1c measurement as other studies have examined.

New research from McGill University investigators details the risk-benefit ratio of antiglycemic agents, including SGLT2 inhibitors, GLP-1RAs, and DPP-4i, on cardiovascular risk reduction among patients with diabetes.

The ASCEND trial indicates low-dose aspirin use was associated with a nonsignificant reduction in risk of dementia among patients with diabetes and no history of cardiovascular disease.

Data from the ASCEND trial provide clinicians with insight into the risk of dementia based on long-term use of low-dose aspirin among patients with diabetes and no history of cardiovascular disease.

The least selected attributes were food and medication restrictions and A1c lowering followed by risk of diabetic ketoacidosis, risk of genital infection, and the avoidance of severe hypoglycemia.

A recent study published in JAMA Network Open describes the impact of the COVID-19 pandemic and related issues on access to insulin among patients with diabetes in the United States.

Data presented at ASN Kidney Week 2021 suggests dapagliflozin use was associated with a reduction in the rate of kidney function decline in patients with chronic kidney disease, regardless of whether they have diabetes.

Results of FIDELITY suggest use of finerenone was associated with reductions in risk of all nonfatal kidney end points included in the analysis, regardless of CKD severity.

An analysis of FIGARO-DKD from Kidney Week 2021 suggests finerenone use was associated with reductions in risk of multiple renal end points, including a 36% reduction in the need for dialysis.

Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.

Using the Steno Type 1 Risk Engine, a team from Denmark conducted a study suggesting SGLT2 inhibition could lower risk of cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes.

An analysis of secondary end points from FIGARO-DKD presented at Kidney Week 2021 provides further insight into the effects of finerenone on kidney outcomes, including a 36% reduction in need for dialysis.

George Bakris, MD, takes part in a Q&A with Endocrinology Network staff to explore the design of the upcoming FIND-CKD trial and potential research priorities surrounding finerenone moving forward.

Data from the FIDELITY analysis suggests use of finerenone was associated with a significant 20% reduction in end-stage kidney disease as well as reductions in all nonfatal kidney end points included in the study's composite kidney outcome.

A significant decrease of -55.3 insulin fills per week during the pandemic was observed, in comparison to before the pandemic.

Data presented at ACR Convergence 2021 suggest statin initiation was associated with a 32% reduction in risk of cardiovascular disease, 54% reduction in risk of all-cause mortality, and a 33% increase in risk of type 2 diabetes.

An analysis of data from more than 160k adults with type 2 diabetes in Scotland provides insight into the incidence of diabetes remission and factors associated with increased likelihood of achieving remission.

A time-conditional propensity score-matched analysis suggests statin initiation was associated with reductions in risk of cardiovascular disease and all-cause mortality but an increase in the risk of new diabetes in patients with rheumatoid arthritis.

Sulfonylurea and/or insulin deintensification occurred in fewer than 50% of older adults with diabetes within 100 days of a hypoglycemia-associated ED visit.

Our latest endocrine case report features a man in his mid-60’s with a history of diabetes and obesity presenting with left groin pain followed by a syncopal episode. Check out the CT scan and determine the correct diagnosis.

October's endocrine month in review features stories on the new ADA and EASD type 1 diabetes guidance, a phase 2 trial examining oral PTH tablets for osteoporosis, and a 3-part panel discussion focusing on diabetes management in 2021.

A propensity score-matched analysis comparing fracture risk associated with the initiation of SGLT2 inhibitors versus GLP-1RAs or DPP-4 inhibitors indicates use of SGLT2 inhibitors was not associated with an increase in risk of fractures in older patients with type 2 diabetes.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.